Total Revenue

–7% (from $1,622M to $1,513M)

Total revenue declined by approximately 7%, driven by material drops in key segments—Established Brands (–11%) and Biosimilars (–14%)—and by double-digit regional declines in Europe & Canada, Asia Pacific & Japan, and Latin America/MEA/Russia/Africa despite the strong 11% rise in U.S. revenue. " " " " "

Women's Health Revenue

+3.1% (from $449M to $463M)

Women's Health revenue grew modestly by 3.1%, reflecting continued strength in key products such as Nexplanon, which had driven robust growth in previous periods, helping to slightly boost the segment even as other areas faced headwinds. " " " "

Established Brands Revenue

–11% (from $994M to $887M)

Established Brands dropped by 11%, a decline attributable to the impact of loss of exclusivity events and increased competitive pricing pressures on mature products, which had already started affecting previous Q1 trends and continued into Q1 2025. " " " " "

Biosimilars Revenue

–14% (from $164M to $141M)

Biosimilars revenue fell by 14% as declines in mature products like Ontruzant and Renflexis accelerated due to normalized contractual volumes, competitive pricing challenges, and tender timing issues—all factors that were beginning to affect the segment in previous reports and deepened in Q1 2025. " " " " "

United States Revenue

+11% (from $371M to $412M)

U.S. revenue increased by 11%, reflecting strong domestic demand in key categories such as Women's Health, which partly offset declines in other regions; this marked improvement continued prior domestic strength noted in earlier periods. " " " "

Other Geographies*

Declines of double-digits

Revenue in Europe & Canada, Asia Pacific & Japan, and Latin America/MEA/Russia/Africa experienced significant declines (e.g., Europe & Canada fell from $450M to $376M) due to factors such as mandatory pricing revisions, pricing pressures, loss of exclusivity, and FX headwinds—trends that were already emerging in previous periods and intensified in Q1 2025. " " " "

Net Income

–57% (from $201M to $87M)

Net income contracted by nearly 57%, primarily because of a sharp increase in restructuring costs ($86M vs. $23M previously), new acquisition-related costs (e.g., $9M for the Dermavant-related expenses), and a $11M change in contingent consideration, compounded by lower revenues impacting margins relative to prior Q1 performance. " "

Long-term Debt

+2.7% (from $8,705M to $8,936M)

Long-term debt increased modestly by 2.7%, reflecting incremental borrowing (including a $60M draw on the Revolving Credit Facility), minor currency adjustments, and refinancing activities that have gradually shifted the debt composition from the previous period. " " " "

Operating Cash Flow

Nearly flat ($75M vs. $76M)

Operating cash flow remained stable despite the drop in net income, due to proactive working capital management (e.g., factoring of receivables and optimized vendor payment timing) that offset lower operating income seen in Q1 2025 relative to the prior year. " "

Revenue (constant currency)

FY 2025

"$6.125B–$6.325B with a flat midpoint " " "

"About flat versus prior year " " "

no change

Adjusted gross margin

FY 2025

"60% to 61%, about 1 point lower versus last year " "

"60% to 61%, about 1 point lower versus last year " "

no change

SG&A expense

FY 2025

"25% of revenue " "

"25% of revenue " "

no change

R&D expense

FY 2025

"Upper single digits as a percentage of revenue " "

"7% of revenue, excluding IPR&D " "

lowered

Adjusted EBITDA margin

FY 2025

"31% to 32% (with a 31% floor ex‑IPR&D) " " "

"31% to 32% " "

no change

Interest expense

FY 2025

"$510 million, including $25 million related to Dermavant " "

"$510 million for the full year " "

no change

Non‑GAAP tax rate

FY 2025

"22.5% to 24.5% " "

"22.5% to 24.5% " "

no change

Depreciation expense

FY 2025

"$135 million " "

"$135 million " "

no change

Restructuring & manufacturing separation costs

FY 2025

"$325 million to $375 million " "

"$325 million to $375 million " "

no change

Free cash flow before onetime costs

FY 2025

"Approximately $900 million " "

"Exceed $900 million " "

no change

Operating expense savings

FY 2025

"Identified $200 million in savings " "

"Approximately $200 million savings over Q2–Q4 (annualizing to $275M in 2026+) " " "

no change

Foreign exchange impact

FY 2025

"Approximately $200 million negative impact, 300 bps headwind " "

"Initially estimated at a $200 million negative impact " "

no change

Net leverage ratio

FY 2025

no prior guidance

"Targeted to be below 4x by the end of 2025 " " "

no prior guidance

VTAMA Launch Dynamics

Q3 2024: Discussed strong early product traction with a $150 million revenue target and significant OpEx concerns. " " Q2 2024: Not mentioned.

Q1 2025: Emphasized robust early product traction in the atopic dermatitis indication with the same $150 million target, while acknowledging high OpEx and operational risks. " " " "

Consistent focus on strong product uptake coupled with high operational investment; sentiment remains positive on growth but cautious about expense levels.

NEXPLANON Growth Prospects

Q3 2024: Highlighted strong growth performance (11% ex FX, 18% U.S. growth), market leadership, and upcoming 5‑year indication with solid patent protection. " " " " Q2 2024: Detailed positive data from the 5‑year study, robust growth percentages, and strong data exclusivity protection. " " "

Q1 2025: Continued to tout revenue potential exceeding $1 billion, extended indications with FDA submission for a 5‑year label, and maintained confidence despite litigation risks. " " "

Recurring theme with steady optimism about revenue growth and innovation despite similar competitive and litigation challenges.

Capital Allocation and Deleveraging

Q2 2024: Emphasized maintaining dividends as the #1 priority while also highlighting strong free cash flow and disciplined debt reduction using cash cycle management. " " Q3 2024: Focused on robust free cash flow generation supporting dividends and overall financial flexibility. " "

Q1 2025: Announced a strategic shift from dividends to debt reduction, redeploying nearly $200 million to drive down net leverage below 4x, reflecting response to a volatile macro environment and investor concerns. " " " " "

Shift in emphasis—from sustaining dividends while managing cash flow to a more aggressive deleveraging approach driven by investor sentiment.

Dermavant Acquisition and Dermatology Market Entry

Q3 2024: Detailed the acquisition of Dermavant and VTAMA’s role as a strategic entry into U.S. dermatology, outlining expected revenues and integration synergies along with execution risks. " " " " Q2 2024: No discussion on this topic.

Q1 2025: Reiterated the acquisition and highlighted VTAMA as a "game changer" with strong revenue forecasts, while also addressing execution risks particularly in integrating new sales and marketing capabilities. " " " " "

Consistent focus on strategic expansion into dermatology with maintained optimism but with persistent acknowledgment of execution and integration risks.

Biosimilars Competition (Hadlima)

Q3 2024: Noted sequential growth in biosimilars overall, with Hadlima’s performance mentioned in the context of overall portfolio growth. " " Q2 2024: Detailed Hadlima’s strong growth momentum (60% prescription growth) alongside competitive challenges from Teva and interchangeability issues. " " "

Q1 2025: Focused on Hadlima’s exceptional 57% growth without highlighting direct competitive challenges (e.g. Teva wins). "

Recurring topic where earlier periods balanced growth with competitive challenges, while Q1 2025’s tone appears more upbeat, downplaying competitive headwinds.

Geographic Growth in China

Q2 2024: Discussed expectations of mid‑single‑digit growth for China, supported by overcoming VBP impacts as 80% of the Established Brands business had undergone VBP. " " Q3 2024: No specific mention.

Q1 2025: Only indirect references to China through fertility business performance, with no explicit mention of mid‑single‑digit expansion or VBP impacts. " "

Topic was detailed in Q2 2024 with future momentum expectations, but less emphasized in Q1 2025 and Q3 2024, suggesting a temporary de‐emphasis.

R&D Pipeline Visibility and Innovation Spending

Q2 2024: Adopted a cautious and prudent approach with emphasis on targeted, “tuck‑in” deals and careful evaluation in Women’s Health, raising mild concerns about long‑term innovation. " Q3 2024: Presented a more positive view with good near‑term pipeline visibility and advancement of key biosimilar candidates. " "

Q1 2025: Did not explicitly highlight long‑term growth concerns regarding R&D, instead focusing on cost management and select innovation drivers such as late‑2025 launches. " " " " "

Mixed sentiment across periods: cautious tone in Q2 2024 shifted to a more upbeat, stable view in Q3 2024 and Q1 2025, indicating a recalibration of innovation spending strategy.

Financial Discipline vs Operating Margin Pressures

Q2 2024: Discussed stable operating margins amid LOE, VBP, and pricing pressures while highlighting strong free cash flow ($1B) and robust adjusted EBITDA margins (31%‑33%). " " " " Q3 2024: Reinforced strong free cash flow and disciplined cost management despite regulatory pricing challenges and LOE impacts. " " " " "

Q1 2025: Emphasized robust free cash flow generation (over $900M), continued strong EBITDA growth, and outlined specific operating margin pressures due to pricing revisions and LOE (e.g., Atozet in Europe), while continuing cost-saving initiatives. " " " " "

Consistent commitment to financial discipline across all periods, with recurring challenges from regulatory pricing and LOE being offset by strong free cash flow and targeted cost savings.